Palavras-chave
Pós-menopausa
Terapia de reposição hormonal
Como Citar
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Resumo
Objetivo: Explorar as evidências científicas disponíveis sobre a ação da terapia hormonal transdérmica em parâmetros clínicos e laboratoriais associados ao risco cardiovascular em mulheres no período pós-menopausal. Métodos: Trata-se de uma revisão integrativa desenvolvida com critérios da estratégia PICO, realizado por meio de pesquisas na base de dados PubMed Central (PMC), Periódico CAPES e Biblioteca Virtual em Saúde (BVS), utilizando os descritores “HormoneReplacementTherapy’’, ‘’Postmenopause’’ e “Cardiovascular Diseases” em combinação com o termo booleano “AND”. Dessa busca, foram analisados 3.282 e, depois de passados por critérios de inclusão e exclusão, foram selecionados 18 artigos para compor o artigo. Resultados: A terapia hormonal transdérmica mostrou benefícios sobre a função endotelial, perfil lipídico, marcadores inflamatórios e risco cardiovascular, com menor risco trombótico em comparação à via oral e que seus efeitos são mais favoráveis quando iniciada precocemente. Contudo, os dados ainda são limitados e heterogêneos, dificultando conclusões definitivas. Considerações finais: A terapia hormonal transdérmica é uma opção promissora na redução do risco cardiovascular pós-menopausa, porém ainda são necessários estudos mais robustos para validar sua eficácia e orientar o uso individualizado.
Referências
ABDOUN K, et al. Effect of early menopause and hormone replacement therapy on Aortic Stenosis progression. The Canadian Journal of Cardiology, 2025; 1: 10.
BALASUBRAMANIAN R, et al. Metabolomic effects of hormone therapy and associations with coronary heart disease among postmenopausal women. Circulation: Genomic and Precision Medicine, 2020; 13(6): e002977.
BLONDON M, et al. Comparative venous thromboembolic safety of oral and transdermal postmenopausal hormone therapies among women Veterans. Menopause (New York, N.Y.), 2021; 28(10): 1125–1129.
BONTEMPO S, et al. Use of MHT in women with cardiovascular disease: a systematic review and meta-analysis. Climacteric: The Journal of the International Menopause Society, 2024; 27(1): 93–103.
EL KHOUDARY SR, et al. Menopause transition and cardiovascular disease risk: Implications for timing of early prevention: A scientific statement from the American Heart Association. Circulation, 2020; 142(25): e506–e532.
GOLDŠTAJN MŠ, et al. Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review. Archives of Gynecology and Obstetrics, 2023; 307(6): 1727–1745.
GU Y, et al. The benefits and risks of menopause hormone therapy for the cardiovascular system in postmenopausal women: a systematic review and meta-analysis. BMC Women's Health, 2024; 24(1): 60.
HILSER JR, et al. Effect of menopausal hormone therapy on methylation levels in early and late postmenopausal women. Clinical Epigenetics, 2022; 14(1): 90.
HODIS HN, MACK WJ. Menopausal hormone replacement therapy and reduction of all-cause mortality and cardiovascular disease: It is about time and timing. Cancer Journal (Sudbury, Mass.), 2022; 28(3): 208–223.
JOHANSSON T, et al. Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register-based emulated target trial. BMJ (Clinical Research Ed.), 2024; (387): e078784.
KALENGA CZ, et al. The association between route of post-menopausal estrogen administration and blood pressure and arterial stiffness in community-dwelling women. Frontiers in Cardiovascular Medicine, 2022; 9: 913609.
KARIM R, et al. Effect of menopausal hormone therapy on arterial wall echo morphology: Results from the Early versus Late Intervention Trial with Estradiol (ELITE). Maturitas, 2022; 162: 15–22.
KIM J, et al. Oral postmenopausal hormone therapy and genetic risk on venous thromboembolism: gene-hormone interaction results from a large prospective cohort study. Menopause (New York, N.Y.), 2022; 29(3): 293–303.
KIM JE, et al. A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases. Scientific Reports, 2020; 10(1): 20631.
LEITE G, et al. Duodenal microbiome changes in postmenopausal women: effects of hormone therapy and implications for cardiovascular risk. Menopause (New York, N.Y.), 2022; 29(3): 264–275.
LI S, et al. Effects of hormone replacement therapy on glucose and lipid metabolism in peri- and postmenopausal women with a history of menstrual disorders. BMC Endocrine Disorders, 2021; 21(1): 121.
PAN M, et al. Update on hormone therapy for the management of postmenopausal women. Bioscience Trends, 2022; 16(1): 46–57.
PRENTICE RL, et al. Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50–59 years of age. American Journal of Epidemiology, 2021; 190(3): 365–375.
RENKE G, et al. Cardio-metabolic health and HRT in menopause: Novel insights in mitochondrial biogenesis and RAAS. Current Cardiology Reviews, 2023; 19(4): e060223213459.
RODRIGUEZ DE MORALES YA, ABRAMSON BL. Cardiovascular and physiological risk factors in women at mid-life and beyond. Canadian Journal of Physiology and Pharmacology, 2024; 102(8): 442–451.
SZABÓ R, et al. Hormone replacement therapy and aging: A potential therapeutic approach for age-related oxidative stress and cardiac remodeling. Oxidative Medicine and Cellular Longevity, 2021; 2021(1): 8364297.
WELLER SC, et al. Hormone exposure and venous thromboembolism in commercially insured women aged 50 to 64 years. Research and Practice in Thrombosis and Haemostasis, 2023; 7(3): 100135.
YOON BK, et al. Effects of menopausal hormone therapy on ambulatory blood pressure and arterial stiffness in postmenopausal Korean women with grade 1 hypertension: a randomized, placebo-controlled trial. Clinical Hypertension, 2021; 27(1): 18.